Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571430 | 1.00 | KLK5 (0.57) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL1133286 | 1.00 | KLK5 (0.57) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL5887534 | 0.93 | CTSS (0.53) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL5887530 | 0.93 | CTSS (0.53) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL1111226 | 0.90 | CTSS (0.50) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL1111230 | 0.90 | CTSS (0.50) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL5887200 | 0.88 | CTSS (0.49) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL5887203 | 0.88 | CTSS (0.49) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL12035376 | 0.88 | KLK5 (0.58) | KLK5CTSSCTSKCTSBCTSL | |
| SCHEMBL16232664 | 0.88 | KLK5 (0.58) | KLK5CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121758479-A | L-4-boron-based phenylalanine and synthesis process and application thereof | 北京新粒科技有限公司 | 2026-03-31 | — | — | CN | disclosed |
| US-12522592-B2 | ERAP inhibitors | UNIVERSITE DE LILLE (FR) | 2026-01-13 | — | — | US | disclosed |
| EP-4263533-B1 | ERAP INHIBITORS | UNIV LILLE (FR) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025106386-A1 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240150933-A1 | AMINO ACID DERIVATIVE-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | META PLATFORMS TECHNOLOGIES, LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240101542-A1 | ERAP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-03-28 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023244554-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| CN-1255912-A | Process for removal of heavy metals | ZAMBON SPA (IT) | 2000-06-07 | — | — | CN | disclosed |
| EP-0981507-A1 | PROCESS FOR THE REMOVAL OF HEAVY METALS | ZAMBON GROUP S.p.A. (IT) | 2000-03-01 | — | — | EP | disclosed |
| EP-0970091-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-ZINC HALIDES | ZAMBON GROUP S.p.A. (IT) | 2000-01-12 | — | — | EP | disclosed |
| EP-0948492-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.p.A. (IT) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999035163-A1 | PHENYLALANINE DERIVATIVES | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999029640-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR | EISAI CO., LTD. (JP) | 1999-06-17 | — | — | WO | disclosed |
| WO-1998051646-A1 | PROCESS FOR THE REMOVAL OF HEAVY METALS | ZAMBON GROUP S.P.A. (IT) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998031687-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-ZINC HALIDES | ZAMBON GROUP S.P.A. (IT) | 1998-07-23 | — | — | WO | disclosed |
| WO-1998028284-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.P.A. (IT) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101542-A1 | ERAP INHIBITORS | ERAP2, ERAP1, ERMP1 | KLK5 4112/4885CTSS 1354/4885CTSK 1240/4885 |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | IL1R1, IL1A, IL1B | KLK5 2728/4885CTSS 1403/4885CTSK 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.